Insufficient scRNA-seq data for expression of PRAME at single-cell level.
Insufficient scRNA-seq data for expression of PRAME at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 99% | 506.67 | 178 / 180 | 85% | 85.92 | 364 / 430 |
skin | 65% | 12.67 | 1173 / 1809 | 96% | 457.83 | 451 / 472 |
uterus | 86% | 121.41 | 146 / 170 | 33% | 58.15 | 151 / 459 |
kidney | 100% | 185.89 | 89 / 89 | 17% | 8.49 | 157 / 901 |
adrenal gland | 100% | 386.50 | 258 / 258 | 7% | 8.09 | 15 / 230 |
lung | 57% | 7.24 | 332 / 578 | 40% | 38.08 | 464 / 1155 |
breast | 67% | 13.27 | 308 / 459 | 25% | 26.95 | 281 / 1118 |
spleen | 88% | 17.64 | 212 / 241 | 0% | 0 | 0 / 0 |
intestine | 83% | 20.51 | 805 / 966 | 3% | 1.65 | 17 / 527 |
heart | 77% | 13.95 | 659 / 861 | 0% | 0 | 0 / 0 |
esophagus | 45% | 5.80 | 653 / 1445 | 26% | 17.00 | 47 / 183 |
brain | 64% | 14.59 | 1686 / 2642 | 2% | 3.63 | 11 / 705 |
muscle | 60% | 13.12 | 481 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 59% | 18.48 | 552 / 929 | 0% | 0 | 0 / 0 |
stomach | 50% | 5.25 | 180 / 359 | 8% | 6.07 | 24 / 286 |
thymus | 52% | 13.72 | 339 / 653 | 7% | 5.73 | 40 / 605 |
adipose | 55% | 14.62 | 665 / 1204 | 0% | 0 | 0 / 0 |
prostate | 53% | 17.33 | 131 / 245 | 1% | 0.47 | 5 / 502 |
liver | 38% | 6.11 | 87 / 226 | 13% | 8.99 | 52 / 406 |
blood vessel | 47% | 7.19 | 634 / 1335 | 0% | 0 | 0 / 0 |
bladder | 33% | 3.76 | 7 / 21 | 13% | 13.02 | 65 / 504 |
eye | 0% | 0 | 0 / 0 | 44% | 121.15 | 35 / 80 |
pancreas | 38% | 3.86 | 126 / 328 | 4% | 2.93 | 7 / 178 |
lymph node | 0% | 0 | 0 / 0 | 38% | 32.68 | 11 / 29 |
tonsil | 0% | 0 | 0 / 0 | 18% | 11.77 | 8 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0048387 | Biological process | negative regulation of retinoic acid receptor signaling pathway |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0030154 | Biological process | cell differentiation |
GO_0006915 | Biological process | apoptotic process |
GO_0045596 | Biological process | negative regulation of cell differentiation |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0005886 | Cellular component | plasma membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0031462 | Cellular component | Cul2-RING ubiquitin ligase complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_1990756 | Molecular function | ubiquitin-like ligase-substrate adaptor activity |
GO_0042974 | Molecular function | nuclear retinoic acid receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PRAME |
Protein name | Melanoma antigen preferentially expressed in tumors (Opa-interacting protein 4) (OIP-4) (Preferentially expressed antigen of melanoma) Melanoma antigen preferentially-expressed in tumors (PRAME nuclear receptor transcriptional regulator) PRAME nuclear receptor transcriptional regulator Melanoma antigen preferentially-expressed in tumors |
Synonyms | MAPE OIP4 |
Description | FUNCTION: Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex, which mediates ubiquitination of target proteins, leading to their degradation . The CRL2(PRAME) complex mediates ubiquitination and degradation of truncated MSRB1/SEPX1 selenoproteins produced by failed UGA/Sec decoding . In the nucleus, the CRL2(PRAME) complex is recruited to epigenetically and transcriptionally active promoter regions bound by nuclear transcription factor Y (NFY) and probably plays a role in chromstin regulation . Functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG: prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis . . |
Accessions | ENST00000438888.5 ENST00000630573.2 ENST00000398743.6 ENST00000617728.4 ENST00000398741.5 P78395 ENST00000631267.1 H7C2P3 ENST00000403441.1 E7EW99 A0A0G2JRX8 ENST00000420709.5 ENST00000627660.2 ENST00000626772.2 ENST00000402697.5 ENST00000628830.2 ENST00000626503.2 ENST00000406503.1 B5MD04 ENST00000630407.2 E7EMH2 B5MCY4 ENST00000543184.5 ENST00000405655.8 ENST00000539862.2 A0A0G2JRX7 ENST00000439106.5 |